ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm developing novel biological therapeutics.
TORONTO - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics, announced today a.
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ - ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel.
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis next generation approach avoids use of DNA and viruses by using mRNA. The technologies will be used for generating iPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-T™ or ExaCAR-NK™ cells.